BRNS BARINTHUS BIOTHERAPEUTICS PL
ADS
CUSIP: 91864C107
FIGI: BBG00ZZPCP09
Institutional Holders13
Total Institutional Value$48,312,722
Total Shares Held7,901,825
Avg Position$3,716,363
Top 5 Holders %99.5%
Alpha-Weighted Score85.8
New Positions+3
Exited Positions-6
Top 15 Institutional Holders by Value
■ New ■ Increased ■ Decreased ■ Unchanged
Institutional Holders — Q4 25
| Manager | Alpha | Flow | Value | Shares | Change |
|---|---|---|---|---|---|
| SC CHINA HOLDING LTD | Elite Conviction | Low Flow | $42,216,458 (87.4%) | 1,420,473 | 2,053.6% |
| M&G PLC | High Conviction | Moderate Flow | $5,197,349 (10.8%) | 5,197,349 | - |
| DC FUNDS, LP | High Conviction | Minimal Flow | $449,607 (0.9%) | 642,204 | -44.0% |
| RENAISSANCE TECHNOLOGIES LLC | High Conviction | Significant Flow | $100,184 (0.2%) | 143,100 | 20.9% |
| JOHNS HOPKINS UNIVERSITY | Elite Conviction | Low Flow | $85,566 (0.2%) | 122,237 | -44.0% |
| CITADEL ADVISORS LLC | Moderate Conviction | Market Mover | $83,171 (0.2%) | 118,799 | NEW |
| BAIRD FINANCIAL GROUP, INC. | High Conviction | Significant Flow | $74,183 (0.2%) | 105,961 | -44.8% |
| RANGELEY CAPITAL, LLC | High Conviction | Minimal Flow | $59,117 (0.1%) | 84,441 | NEW |
| HIGHTOWER ADVISORS, LLC | High Conviction | Significant Flow | $26,219 (0.1%) | 37,450 | -44.0% |
| RHUMBLINE ADVISERS | High Conviction | Market Mover | $8,179 (0.0%) | 11,685 | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | High Conviction | Market Mover | $8,098 (0.0%) | 11,568 | -44.0% |
| MORGAN STANLEY | Moderate Conviction | Market Mover | $2,385 (0.0%) | 3,406 | -61.4% |
| UBS Group AG | Moderate Conviction | Market Mover | $2,206 (0.0%) | 3,152 | 13,687.5% |
Implied Institutional Price History
Estimated from 13F aggregate market value ÷ shares reported across all institutional filers. Reflects quarter-end snapshot, not actual trade prices.
| Quarter | Filers | Institutional Value | Shares Held | Est. Avg Price |
|---|---|---|---|---|
| Q4 25 | 13 | $0.05B | 7,901,825 | $6.11 |
| Q3 25 | 15 | $0.01B | 9,172,174 | $1.12 |
| Q2 25 | 14 | $0.01B | 9,309,661 | $0.97 |
| Q1 25 | 14 | $0.01B | 9,485,402 | $0.96 |
| Q4 24 | 16 | $0.01B | 9,725,412 | $1.06 |
| Q3 24 | 19 | $0.01B | 9,710,499 | $1.09 |
| Q2 24 | 18 | $0.01B | 9,936,458 | $1.17 |
| Q1 24 | 15 | $0.02B | 9,723,933 | $2.16 |
Source: SEC 13F-HR filings. Implied price = aggregate market value ÷ shares reported. Not investment advice.